business news in context, analysis with attitude

With brief, occasional, italicized and sometimes gratuitous commentary…

•  From the New York Times:

"Amazon said on Wednesday that it was removing seven eyedrops products from its website after the Food and Drug Administration warned the company that the eyedrops had not been recognized as safe and effective.

"The F.D.A. said in a letter to Andrew Jassy, Amazon’s chief executive, on Monday that Amazon had violated federal regulations by selling the eyedrops, which claimed to help with problems including pink eye, dry eyes, eyestrain and floaters.

"'These products are especially concerning from a public health perspective,' the F.D.A. letter said. 'Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.'

"The eyedrops named in the letter are: Similasan Pink Eye Relief, The Goodbye Company Pink Eye, Can-C Eye Drops, Optique 1 Eye Drops, OcluMed Eye Drops, TRP Natural Eyes Floaters Relief, and Manzanilla Sophia Chamomile Herbal Eye Drops."

There is no excuse for Amazon needing a warning because it is out of compliance with federal regulations with which other retailers already have complied.  It ought to be first, not last.